Predictors of survival after transarterial radioembolization in patients with hepatocellular carcinoma

Introduction: Transarterial radioembolization with yttrium-90–based microspheres (TARE) is an established therapy for patients with advanced non-metastatic hepatocellular carcinoma (HCC). However, factors associated with short or long survival are not completely clear. Objectives: To examine a cohort of patients not candidates for surgery who were treated with TARE and had known survival duration to document and compare the characteristics of those with shorter versus longer survival times. Methods: HCC patients (n = 308) were treated exclusively with TARE and followed until death. Their baseline and follow-up blood clinical parameters were retrospectively analyzed. Patients were categorized into short-term (<11 months) and long-term (>11 months) survivors according to the cohort median survival. Results: The longer- and shorter-survival groups differed significantly in maximum tumor diameter (MTD), multifocality, portal vein thrombosis (PVT), albumin-bilirubin (ALBI), modified ALBI, platelet-ALBI grades, alpha-fetoprotein (AFP), albumin, liver function parameters, and C-reactive protein. In multivariable logistic regression, MTD, multifocality, AFP, albumin, and hemoglobin had significant odds ratios. Patients with PVT were represented in both survival groups. In the longer-survival PVT group, multifocality was significantly less frequent, and MTD, platelet-ALBI grade, aspartate aminotransferase, gamma-glutamyl transferase, and C-reactive protein were lower, while albumin was higher. Increased albumin post-TARE was significantly associated with increased survival, independent of baseline AFP. Patients with normal bilirubin in the total cohort were dichotomized by albumin level. Lower albumin was associated with poorer survival and higher baseline inflammation markers, with no change in tumor factors. Increased albumin or decreased AFP post-TARE were each associated with increased survival. Conclusion: Baseline tumor and inflammation parameters were independently associated with survival post-TARE, as were increased albumin and decreased AFP in response to TARE.

Authors

Institutions

Publication Details

Journal
Eurasian Journal of Medicine and Oncology
Published
2026-11-16
DOI
https://doi.org/10.36922/ejmo026330420
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Predictors of survival after transarterial radioembolization in patients with hepatocellular carcinoma

Ramazan Kutlu, Yilmaz Sezai, Harika Gozukara Bag, Brian Irving Carr et al.
Eurasian Journal of Medicine and Oncology
Hepatocellular Carcinoma Treatment and Prognosis
article

Predictors of survival after transarterial radioembolization in patients with hepatocellular carcinoma

Ramazan Kutlu, Yilmaz Sezai, Harika Gozukara Bag, Brian Irving Carr, Ince Volkan
article en

Abstract

Introduction: Transarterial radioembolization with yttrium-90–based microspheres (TARE) is an established therapy for patients with advanced non-metastatic hepatocellular carcinoma (HCC). However, factors associated with short or long survival are not completely clear. Objectives: To examine a cohort of patients not candidates for surgery who were treated with TARE and had known survival duration to document and compare the characteristics of those with shorter versus longer survival times. Methods: HCC patients (n = 308) were treated exclusively with TARE and followed until death. Their baseline and follow-up blood clinical parameters were retrospectively analyzed. Patients were categorized into short-term (<11 months) and long-term (>11 months) survivors according to the cohort median survival. Results: The longer- and shorter-survival groups differed significantly in maximum tumor diameter (MTD), multifocality, portal vein thrombosis (PVT), albumin-bilirubin (ALBI), modified ALBI, platelet-ALBI grades, alpha-fetoprotein (AFP), albumin, liver function parameters, and C-reactive protein. In multivariable logistic regression, MTD, multifocality, AFP, albumin, and hemoglobin had significant odds ratios. Patients with PVT were represented in both survival groups. In the longer-survival PVT group, multifocality was significantly less frequent, and MTD, platelet-ALBI grade, aspartate aminotransferase, gamma-glutamyl transferase, and C-reactive protein were lower, while albumin was higher. Increased albumin post-TARE was significantly associated with increased survival, independent of baseline AFP. Patients with normal bilirubin in the total cohort were dichotomized by albumin level. Lower albumin was associated with poorer survival and higher baseline inflammation markers, with no change in tumor factors. Increased albumin or decreased AFP post-TARE were each associated with increased survival. Conclusion: Baseline tumor and inflammation parameters were independently associated with survival post-TARE, as were increased albumin and decreased AFP in response to TARE.

Eurasian Journal of Medicine and OncologyVol. 0(0)
Inonu University (TR)
Good health and well-being
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon